Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells 2,064 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 2,064 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $64.14, for a total transaction of $132,384.96. Following the completion of the sale, the director directly owned 1,785,242 shares in the company, valued at $114,505,421.88. This represents a 0.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Liquidia Stock Performance

LQDA stock traded up $2.05 during trading on Monday, hitting $63.90. 3,158,836 shares of the company’s stock traded hands, compared to its average volume of 1,717,868. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 52 week low of $11.85 and a 52 week high of $66.78. The stock has a fifty day moving average price of $46.78 and a two-hundred day moving average price of $39.64. The stock has a market capitalization of $5.68 billion, a price-to-earnings ratio of 456.46 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. The business’s revenue was up 4187.1% on a year-over-year basis. As a group, equities analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Hedge Funds Weigh In On Liquidia

Several large investors have recently made changes to their positions in LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Liquidia by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after purchasing an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after purchasing an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after purchasing an additional 16,022 shares during the last quarter. Creative Planning lifted its position in shares of Liquidia by 40.7% during the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after purchasing an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Liquidia by 13.4% during the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after purchasing an additional 11,111 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on LQDA. Zacks Research raised shares of Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Oppenheimer set a $75.00 price objective on shares of Liquidia in a research note on Friday. Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Wells Fargo & Company lifted their price objective on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Finally, HC Wainwright lifted their price objective on shares of Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research note on Friday. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and an average price target of $55.63.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).